Meeting
2011 ASCO Annual Meeting
Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
Authors
D. Adkins
Washington University School of Medicine, St. Louis, MO
D. Adkins , J. Ley , B. Nussenbaum , J. Diaz , R. Paniello , W. L. Thorstad , H. A. Gay , J. Subramanian , T. M. Wildes , J. Mathai , T. Rachocki , D. I. Kuperman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00736944
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5560)
Abstract #
5560
Poster Bd #
14G
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
Poster
2023 ASCO Annual Meeting
Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.
First Author: Ghanashyam Biswas
Poster
2019 ASCO Annual Meeting
Randomized phase II study with or without induction chemotherapy combined with accelerated high dose radiotherapy and cetuximab in locally advanced unresectable HPV positive squamous cell carcinoma of the head and neck.
First Author: Signe Friesland
Poster
2016 ASCO Annual Meeting
TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.
First Author: Pol M. Specenier